Skip to main content
Journal cover image

MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study

Publication ,  Conference
Harrison, S; Moussa, S; Bashir, M; Alkhouri, N; Frias, J; Baum, S; Tetri, B; Bansal, M; Taub, R
Published in: Journal of Hepatology
April 2018

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Journal of Hepatology

DOI

ISSN

0168-8278

Publication Date

April 2018

Volume

68

Start / End Page

S38 / S38

Publisher

Elsevier BV

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Harrison, S., Moussa, S., Bashir, M., Alkhouri, N., Frias, J., Baum, S., … Taub, R. (2018). MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study. In Journal of Hepatology (Vol. 68, pp. S38–S38). Elsevier BV. https://doi.org/10.1016/s0168-8278(18)30292-7
Harrison, S., S. Moussa, M. Bashir, N. Alkhouri, J. Frias, S. Baum, B. Tetri, M. Bansal, and R. Taub. “MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study.” In Journal of Hepatology, 68:S38–S38. Elsevier BV, 2018. https://doi.org/10.1016/s0168-8278(18)30292-7.
Harrison S, Moussa S, Bashir M, Alkhouri N, Frias J, Baum S, et al. MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study. In: Journal of Hepatology. Elsevier BV; 2018. p. S38–S38.
Harrison, S., et al. “MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study.” Journal of Hepatology, vol. 68, Elsevier BV, 2018, pp. S38–S38. Crossref, doi:10.1016/s0168-8278(18)30292-7.
Harrison S, Moussa S, Bashir M, Alkhouri N, Frias J, Baum S, Tetri B, Bansal M, Taub R. MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study. Journal of Hepatology. Elsevier BV; 2018. p. S38–S38.
Journal cover image

Published In

Journal of Hepatology

DOI

ISSN

0168-8278

Publication Date

April 2018

Volume

68

Start / End Page

S38 / S38

Publisher

Elsevier BV

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences